<DOC>
	<DOC>NCT00930904</DOC>
	<brief_summary>The purpose of this study is to evaluate long-term performance of the 4196 LV Lead. This evaluation is based on the number of lead-related complications occurring during the study compared to the number of leads enrolled in the study. The leads will be followed for 5 years after implant. This study is required by FDA as a condition of approval of the Model 4196 LV Lead and is integrated within the Product Surveillance Registry (PAN Registry).</brief_summary>
	<brief_title>Model 4196 Left Ventricular (LV) Lead Chronic Performance Study</brief_title>
	<detailed_description>Model 4196 LV lead complication-free survivability will be summarized.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Patients who meet all of the following inclusion criteria and do not meet any of the following exclusion criteria are eligible for enrollment. Inclusion Criteria Patient or legally authorized representative provides written authorization and/or consent per institution and geographical requirements Patient has or is intended to receive an Attain Ability Model 4196 LV lead Patient within 30 day post implant enrollment window Exclusion Criteria Patient who is, or is expected to be inaccessible for followup Patient with exclusion criteria required by local law Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound results</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>